CAR T Cell Therapy Market, By Targeted Antigen (CD19, BCMA, HER2, GD2, CD20, CD22, CD30, CD33, HER1, Others (CLDN18, etc.)), By Therapeutic Application (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma (DLBCL), Folli

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	222 Pages	Coherent Market Insights	January, 2023	CMI17712934

Best Price Guarantee
Price	from $4,500
Length	222 Pages
Publisher	Coherent Market Insights
Published Date	January, 2023
SKU	CMI17712934

CAR T Cell Therapy Market, By Targeted Antigen (CD19, BCMA, HER2, GD2, CD20, CD22, CD30, CD33, HER1, Others (CLDN18, etc.)), By Therapeutic Application (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Glioblastoma, Sarcoma, Neuroblastoma, Acute Myeloid Leukemia, Breast Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Others (Gastric Cancer, etc.)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Chimeric antigen receptor (CAR)-T cell therapy is a type of immunotherapy which uses immune T cells to destroy cancer. CAR T cell therapy is also called as cell based gene therapy, as it involves gene altering in T cells. For chimeric antigen receptor (CAR)-T cell therapy, T cells are extracted from human body using a procedure called leukapheresis. Then after extraction, T cells are altered by adding the gene for the specific chimeric antigen receptor (CAR) and hence they are called as CAR T cells. After the alteration, the cells are kept to grow and then are infused into human body. Different type of CAR T cell therapy are made to fight specific type of cancer. CAR- T cells are customized for different patients and then infused in blood. CAR T cells therapy is used as a novel gene therapy to fight cancer. Different clinical and preclinical studies are going on to study the safety and efficacy of various CAR-T cell therapies for specific cancer. Moreover, several governments are taking initiatives such as campaigns to spread the awareness of cancer for example educational campaign by Centers for Disease Control and Prevention (CDC).

Market Dynamics

Increasing adoption of organic strategies by key players in market such as product approval is expected to drive market growth over the forecast period. For instance, in May 2022, Novartis AG., one of the global healthcare company, received the U.S. Food and Drug Administration approval for Kymriah (tisagenlecleucel) CAR-T cell therapy for the treatment of adult patients with relapsed or refractory follicular lymphoma. The approval is based on phase II clinical trial, evaluated with 68% of positive response from the patients.

Key features of the study:

This report provides in-depth analysis of the global CAR T cell therapy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global CAR T cell therapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, CARsgenTherapeutics Co.,Ltd, Aurora Biopharma, Legend Biotech, Gilead Sciences, Inc., Pfizer Inc., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics among other prominent players
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global CAR T cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global CAR T cell therapy market

Detailed Segmentation:

Global CAR T Cell Therapy Market, By Targeted Antigen:
CD19
BCMA
HER2
GD2
CD20
CD22
CD30
CD33
HER1
Others (CLDN18, etc.)
Global CAR T Cell Therapy Market, By Therapeutic Application:
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Diffuse Large B-cell Lymphoma (DLBCL)
Follicular Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Glioblastoma
Sarcoma
Neuroblastoma
Acute Myeloid Leukemia
Breast Cancer
Pancreatic Cancer
Hepatocellular Carcinoma
Colorectal Cancer
Others (Gastric Cancer, etc.)
Global CAR T Cell Therapy Market, By Region:
North America
By Country
U.S.
Canada
Latin America
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Country
GCC
Israel
Rest of Middle East
Africa
By Region/Country
South Africa
Central Africa
North Africa
Company Profiles
Bristol-Myers Squibb Company
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Johnson & Johnson Services, Inc.
Novartis AG
CARsgenTherapeutics Co., Ltd
Aurora Biopharma
Legend Biotech
Gilead Sciences, Inc.
Pfizer Inc.
bluebird bio, Inc.
Sorrento Therapeutics, Inc.
Mustang Bio
Fate Therapeutics

“*” marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snapshot, By Targeted Antigen; Market Snapshot, By Therapeutic Application; Market Snapshot, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Opportunities; Impact Analysis; Market Trends; Recent Developments; Acquisitions and Partnerships Scenario; Regulatory Scenario; Pipeline Analysis; PEST Analysis; Porter’s Analysis
4. Global CAR T Cell Therapy Market– COVID-19 Impact Analysis: Overall Impact; Impact on Supply and Demand; COVID-19 Impact on the market
5. Global CAR T Cell Therapy Market, By Targeted Antigen, 2017 – 2030, (US$ Million): Overview; Market Share Analysis, 2022 and 2030 (%); Y-o-Y Growth Analysis, 2017 – 2030; Segment Trends; CD19; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); BCMA; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); HER2; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); GD2; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); CD20; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); CD22; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); CD30; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); CD33; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); HER1; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Others (CLDN18, etc.); Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
6. Global CAR T Cell Therapy Market, By Therapeutic Application, 2017 – 2030, (US$ Million): Overview; Market Share Analysis, 2022 and 2030 (%); Y-o-Y Growth Analysis, 2017 – 2030; Segment Trends; Acute Lymphocytic Leukemia; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Chronic Lymphocytic Leukemia; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Diffuse Large B-cell Lymphoma (DLBCL); Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Follicular Lymphoma; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Mantle Cell Lymphoma; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Multiple Myeloma; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Glioblastoma; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Sarcoma; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Neuroblastoma; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Acute Myeloid Leukemia; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Breast Cancer; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Pancreatic Cancer; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Hepatocellular Carcinoma; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Colorectal Cancer; Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Others (Gastric Cancer, etc.); Overview; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
7. Global CAR T Cell Therapy Market, By Region, 2017 – 2030, (US$ Million): Introduction; Market Share Analysis, By Region, 2022 and 2030 (%); Y-o-Y Growth Analysis, For Regions, 2017–2030; Regional Trends; North America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million); U.S.; Canada; Latin America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million); Brazil; Mexico; Argentina; Rest of Latin America; Europe; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million); UK; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million); China; India; Japan; ASEAN; Australia; South Korea; Rest of Asia Pacific; Middle East; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million); GCC; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million); North Africa; Central Africa; South Africa
8. Competitive Landscape: Bristol-Myers Squibb Company; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Johnson & Johnson Services, Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Novartis AG; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; CARsgenTherapeutics Co.,Ltd; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Aurora Biopharma; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Legend Biotech; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Gilead Sciences, Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Pfizer Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; bluebird bio, Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; SorrentTherapeutics, Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Mustang Bio; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Fate Therapeutics; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies
9. Section: Research Methodology; About Us; *Browse 32 market data tables and 24 figures on "Global CAR T Cell Therapy Market” - forecast t2030